MAOA and central nervous system cancer: In TMZ-sensitive and TMZ-resistant human glioma cells, PAMs inhibited MAO-A catalytic activity and decreased glioma cell growth, colony formation, and cell migration, while in an in vivo mouse glioblastoma model, this treatment limited tumor growth and increased the survival rate.